13F Holdings
中文EN

ABPO Abpro Holdings, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x

Cash quality & payout

Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue—$183,000$122,000—
R&D expense$989,000$2.98M$4.27M—
SG&A expense$7.46M$7.12M$7.60M—
Operating income-$8.45M-$9.92M-$11.75M-$2.05M
Interest expense$1.13M$387,000$23,000—
Pretax income—-$7.23M-$11.71M$1.71M
Income tax——$1.18M$823,991
Net income-$2.89M-$7.23M$2.82M$886,918
EBITDA-$8.43M-$9.85M-$11.47M—
EPS (basic)-1.30-22.31-0.61—
EPS (diluted)-1.30-22.31-0.61—
Weighted avg. shares (diluted)2.23M780,33219.13M—
Balance sheet
Cash & equivalents$82,000$2.99M$861,000$7.46M
Receivables$183,000$183,000$88,000—
Current assets$896,000$3.78M$2.04M$770,226
PP&E, net—$37,000$102,000—
Total assets$1.06M$4.66M$3.35M$310.56M
Current liabilities$9.35M$19.61M$15.74M$2.14M
Total liabilities$9.35M$19.61M$16.19M$15.29M
Shareholders' equity-$8.83M-$15.49M-$88.98M-$11.18M
Shares outstanding2.73M1.69M19.17M—
Cash flow statement
Operating cash flow-$6.01M-$9.03M-$7.40M-$1.18M
Capital expenditure——$48,000—
Free cash flow——-$7.45M—
Investing cash flow——$278.44M-$305.67M
Financing cash flow$3.07M$11.16M$849,000$307.25M
Depreciation & amortization$21,000$74,000$279,000—
Stock-based compensation$1.49M$1.93M$2.31M$362,500
Share buybacks——$276.47M$0

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.